Clinical trials: Elevated PSA
Metastatic Prostate Cancer
Human Telomerase Reverse Transcriptase Messenger RNA (hTERT mRNA) Transfected Dendritic Cell Vaccines
The purpose of this research is to develop a new and powerful type of immune therapy for prostate cancer patients. This therapy involves vaccinations with special stimulator cells found in the human body called dendritic cells.
- Trial name
- NCT01153113
- Testing
- hTERT mRNA DC
- Sponsor
- University of Florida
Health Status Unknown, Elevated PSA
Diagnosing Clinically Significant Prostate Cancer In African American and White Men With Elevated PSA
This randomized phase II trial studies how well systematic random biopsy or magnetic resonance imaging (MRI)-ultrasound image (US) fusion biopsy work in diagnosing prostate cancer in patients with elevated prostate specific…
- Trial name
- NCT03234556
- Testing
- Biopsy of Prostate, Laboratory Biomarker Analysis, Magnetic Resonance Imaging
- Where
- 4 sites in United States
- Volunteers
- 288 people
- Sponsor
- University of Southern California
Prostate Cancer
Safety, Pharmacokinetic and Proof-of-Concept Study of ARN-509 (Apalutamide) in Castration-Resistant Prostate Cancer (CRPC)
The purpose of this study is to assess the safety and activity of ARN-509 in men with advanced castration resistant prostate cancer.
- Trial name
- NCT01171898
- Testing
- ARN-509 (Phase 1), ARN-509 (Phase 2)
- Where
- 15 sites in United States
- Volunteers
- 127 people
- Sponsor
- Aragon Pharmaceuticals, Inc.
Prostate Cancer
Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising Prostate Specific Antigen (PSA) After Surgery for Prostate Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Androgens can cause the growth of prostate cancer cells.
- Trial name
- NCT00567580
- Testing
- PBRT, PLNRT, AA
- Where
- 460 sites in United States, Canada and 2 more
- Volunteers
- 1,792 people
- Sponsor
- Radiation Therapy Oncology Group
Prostate Cancer, Metastases
A Research Study for Patients With Prostate Cancer
The purpose of this study is to evaluate the activity of romidepsin (depsipeptide,FK228) in patients with metastatic prostate cancer who have developed a rising prostate specific antigen (PSA) while undergoing hormonal therapy.
- Trial name
- NCT00106418
- Testing
- Romidepsin
- Volunteers
- 35 people
- Sponsor
- Celgene
Prostate Cancer
YM598 in Patients With Rising PSA After Initial Therapy for Localized Prostate Cancer
The purpose of this study is to determine the optimal dosage of YM598 for slowing down disease progression in patients with rising PSA after initial therapy for localized prostate cancer.
- Trial name
- NCT00050297
- Testing
- YM598
- Where
- 23 sites in Belgium, Czechia and 5 more
- Sponsor
- Astellas Pharma Inc
Prostate Cancer, Elevated PSA
Upright MRI for Prostate Cancer Screening
This is an investigator initiated study to test the efficacy of an upright MRI (Magnetic Resonance Imaging) for the screening of prostate cancer.
- Conditions
- Prostate Cancer, Elevated PSA, Elevated Prostate Specific Antigen
- Trial name
- NCT03474913
- Testing
- Upright MRI, Standard MRI
- Where
- United States
- Volunteers
- 550 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Prostate Cancer (Adenocarcinoma), Adenocarcinoma of the Prostate
RYZ711 Diagnostic Platform Study
This is a Phase 1/2 multicenter, multi-cohort imaging study to evaluate the safety, tolerability, and diagnostic performance of RYZ711 positron emission tomography/computed tomography (PET/CT) in men with histologically confirmed…
- Conditions
- Prostate Cancer (Adenocarcinoma), Adenocarcinoma of the Prostate, Metastatic Castration-resistant Prostate Cancer (mCRPC), Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
- Trial name
- NCT07862582
- Testing
- RYZ711, PSMA PET/CT
- Where
- United States
- Volunteers
- 116 people
- Sponsor
- RayzeBio, Inc.
Prostate Cancer
Atorvastatin Calcium and Celecoxib in Treating Patients With Rising PSA Levels After Local Therapy for Prostate Cancer
RATIONALE: Atorvastatin calcium and celecoxib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving atorvastatin calcium together with celecoxib may kill more tumor cells.
- Trial name
- NCT01220973
- Testing
- atorvastatin calcium, celecoxib, laboratory biomarker analysis
- Where
- 4 sites in United States
- Volunteers
- 27 people
- Sponsor
- Rutgers, The State University of New Jersey
Prostate Cancer
Sorafenib in Hormone Naïve Biochemical Recurrence of Prostate Cancer
The purpose of this study is to measure the benefit of sorafenib in patients with a rising PSA after treatment with radiation therapy or surgery who are NOT receiving with androgen ablation therapy.
- Trial name
- NCT00694291
- Testing
- Sorafenib
- Where
- United States
- Sponsor
- Fox Chase Cancer Center
PSA, Elevated PSA
Marker Driven Selection of Patients for Prostate Biopsy and Management
The purpose of this research study is to determine if the interpretation of multiparametric MRI (mpMRI) with an algorithm called habitat risk score (HRS) in combination with a panel of blood and urine biomarkers is more effective…
- Conditions
- PSA, Elevated PSA, Prostate Cancer
- Trial name
- MDSelect (NCT04240327)
- Where
- United States
- Volunteers
- 289 people, healthy volunteers welcome
- Sponsor
- University of Miami
Postoperative or Postradiation Adjuvant Androgen Deprivation Therapy in Locally Advanced Prostate Cancer (High and Very High Risk) Patients
Non-Interventional Study PREVENT
This is a multicentre, non-interventional, prospective study to be carried out in representative medical institutions in order to get the information on administration of postoperative and post-radiation adjuvant androgen…
- Trial name
- PREVENT (NCT02155998)
- Where
- 14 sites in Russia
- Volunteers
- 200 people
- Sponsor
- AstraZeneca
Prostatic Neoplasms
A Study of Androgen Deprivation With Leuprolide, +/- Docetaxel for Clinically Asymptomatic Prostate Cancer Participants With a Rising Prostate Specific Antigen (PSA)
The primary objective was to evaluate and compare the efficacy of androgen deprivation with or without docetaxel as determined by the median progression free survival (PFS) over the period of 18-month therapy and at least…
- Trial name
- Rising PSA (NCT00514917)
- Testing
- Docetaxel, Leuprolide, Bicalutamide
- Where
- 9 sites in United States, Belgium and 7 more
- Volunteers
- 413 people
- Sponsor
- Sanofi
Prostate Cancer
Targeted Prostate Biopsy Using a Novel MRI-Ultrasound Fusion Device
The purpose of this study is to evaluate the effectiveness of Focal-Fusion Bx at detecting clinically significant prostate cancer in a standard clinical environment.
- Trial name
- NCT02524860
- Testing
- Focal-Fusion Bx
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Focal Healthcare Inc.
Prostate Cancer
Positron Emission Tomography / Magnetic Resonance Imaging (PET/MRI) Guided Biopsy in Men With Elevated PSA
In 22% of patients with elevated Prostate-specific antigen (PSA) MRI guided biopsy will not detect significant prostate cancer (PCA) (defined as either: Gleason score (GS) ≥ 3+4 or tertiary pattern 5, or final stage ≥ pT3a and/or…
- Trial name
- NCT03187990
- Testing
- [68Ga]PSMA-11, [18F]PSMA-1007
- Where
- Switzerland
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Irene Burger
Prostate Adenocarcinoma, PSA Level Greater Than 0.2
F18 DCFPyL PET/CT in Imaging Participants With Recurrent Prostate Cancer
This study provides fluorine F 18 DCFPyL positron emission tomography/computed tomography (PET/CT) to participants with prostate cancer that has come back.
- Conditions
- Prostate Adenocarcinoma, PSA Level Greater Than 0.2, PSA Level Greater Than or Equal to Two, PSA Progression
- Trial name
- NCT03501940
- Testing
- Computed Tomography, Fluorine F 18 DCFPyL, Laboratory Biomarker Analysis
- Where
- United States
- Sponsor
- Andrei Iagaru
Prostate Cancer
Phase 2 Trial of Enzastaurin in Prostate Cancer in Participants Who Have Had Hormonal and Chemotherapy
The purpose is to see how quickly two different types of prostate cancer participants respond when taking enzastaurin. Cohort 1 - asymptomatic participants with androgen-independent prostate-specific antigen (PSA)-progressive…
- Trial name
- NCT00428714
- Testing
- enzastaurin
- Where
- 11 sites in United States
- Volunteers
- 73 people
- Sponsor
- Eli Lilly and Company
Adenocarcinoma of the Prostate
A Prospective Randomized Phase III Study Comparing Hormonal Therapy +/-Docetaxel
The primary objective was to evaluate the PSA (biochemical) progression-free survival (PFS) of high-risk metastasis-free PC patients, treated with LH-RH agonist for one year with or without docetaxel after prior radical…
- Trial name
- RisingPSA (NCT00764166)
- Testing
- Docetaxel + hormonal treatment (LH-RH agonist), Hormonal treatment (LH-RH agonist)
- Where
- France
- Volunteers
- 254 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Neoplasms, Prostate
Prostate Cancer Study In Men Who Have Failed First-Line Androgen Deprivation Therapy
Dutasteride inhibits the conversion of testosterone to dihydrotestosterone (DHT) the male hormone that leads to benign prostate growth.
- Trial name
- NCT00470834
- Testing
- dutasteride, bicalutamide
- Where
- 62 sites in United States, Canada
- Volunteers
- 127 people
- Sponsor
- GlaxoSmithKline
Prostate Cancer
Carbohydrate Restriction and Prostate Cancer Growth
No treatments have been shown to slow prostate cancer progression after radical prostatectomy. We hypothesize that a carbohydrate restricted diet will slow prostate cancer growth.
- Trial name
- CAPS2 (NCT01763944)
- Testing
- Low carbohydrate diet
- Where
- 3 sites in United States
- Volunteers
- 83 people
- Sponsor
- Duke University